Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background/Objective: Patients with posterior cortical atrophy (PCA) often have Alzheimer disease (AD) at autopsy, yet are cognitively and anatomically distinct from patients with clinical AD. We sought to compare the distribution of β-amyloid and glucose metabolism in PCA and AD in vivo using Pittsburgh compound B (PiB) and FDG-PET.
Methods: Patients with PCA (n = 12, age 57.5 ± 7.4, Mini-Mental State Examination [MMSE] 22.2 ± 5.1), AD (n = 14, age 58.8 ± 9.6, MMSE 23.8 ± 6.7), and cognitively normal controls (NC, n = 30, age 73.6 ± 6.4) underwent PiB and FDG-PET. Group differences in PiB distribution volume ratios (DVR, cerebellar reference) and FDG uptake (pons-averaged) were assessed on a voxel-wise basis and by comparing binding in regions of interest (ROIs).
Results: Compared to NC, both patients with AD and patients with PCA showed diffuse PiB uptake throughout frontal, temporoparietal, and occipital cortex (p < 0.0001). There were no regional differences in PiB binding between PCA and AD even after correcting for atrophy. FDG patterns in PCA and AD were distinct: while both groups showed hypometabolism compared to NC in temporoparietal cortex and precuneus/posterior cingulate, patients with PCA further showed hypometabolism in inferior occipitotemporal cortex compared to both NC and patients with AD (p < 0.05). Patients with AD did not show areas of relative hypometabolism compared to PCA.
Conclusions: Fibrillar amyloid deposition in PCA is diffuse and similar to AD, while glucose hypometabolism extends more posteriorly into occipital cortex. Further studies are needed to determine the mechanisms of selective network degeneration in focal variants of AD.
Footnotes
Study funding: Supported by the NIH/NIA K23-AG031861, R01-AG027859, P01-AG1972403, P50 AG023501, Alzheimer's Association NIRG-07-59422, ZEN-08-87090, John Douglas French Alzheimer's Foundation, and State of California DHS-ADRC 04-33516.
-
Editorial, page 1778
-
See page 1782
-
Supplemental data at www.neurology.org
-
- AD
- Alzheimer disease
- DVR
- distribution volume ratio
- FWE
- family-wise error
- LPA
- logopenic aphasia
- MMSE
- Mini-Mental State Examination
- MNI
- Montreal Neurological Institute
- NC
- normal control
- NFT
- neurofibrillary tangle(s)
- PCA
- posterior cortical atrophy
- PiB
- Pittsburgh compound B
- PPA
- primary progressive aphasia
- ROI
- region of interest
- VBM
- voxel-based morphometry
- VOSP
- Visual Object and Space Perception battery.
- Received August 9, 2010.
- Accepted November 23, 2010.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementiaMyria Petrou, Nicolaas I. Bohnen, Martijn L.T.M. Müller et al.Neurology, August 29, 2012 -
Articles
Imaging β-amyloid burden in aging and dementiaC. C. Rowe, S. Ng, U. Ackermann et al.Neurology, May 14, 2007 -
Articles
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriersMichael Schöll, Anders Wall, Steinunn Thordardottir et al.Neurology, June 13, 2012 -
Articles
Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer diseaseM.D. Ikonomovic, W.E. Klunk, E.E. Abrahamson et al.Neurology, June 22, 2011


